Skip to main content
Bonus BioGroup Ltd. logo

Bonus BioGroup Ltd. — Investor Relations & Filings

Ticker · BONS ISIN · IL0004850116 TA Professional, scientific and technical activities
Open in API
Filings indexed 9 across all filing types
Latest filing 2025-05-27 Investor Presentation
Country IL Israel
Listing TA BONS

About Bonus BioGroup Ltd.

https://www.bonusbiogroup.com/

Bonus BioGroup Ltd. is a clinical-stage biotechnology company that develops cell therapy and tissue engineering products. The company's research focuses on addressing unmet medical needs related to tissue damage, inflammation, and immune response. Its core technology platforms include an investigational cell therapy designed to modulate inflammation and promote tissue repair using mesenchymal cells, and a viable tissue engineering approach that combines patient-derived cells with biomaterials for bone regeneration. Key product candidates in its pipeline are BonoFill, a personalized, tissue-engineered bone graft for orthopedic and maxillofacial defects, and MesenCure, an allogeneic cell therapy developed to target inflammation and tissue damage. These investigational therapies are currently being evaluated in clinical trials for safety and efficacy.

Recent filings

Filing Released Lang Actions
Company Presentation- 2025
Investor Presentation Classification · 98% confidence The document is an invitation for an investor meeting ('הזמנה למפגש משקיעים') scheduled for June 4, 2025, to discuss company developments, including the submission of a draft registration document to NASDAQ and progress in clinical trials (Phase 3 preparations for Bonopil and MesenCure). Crucially, the text explicitly states: 'מצגת חברה עדכנית, מצורפת להודעה זו' (An updated company presentation is attached to this announcement). The document itself contains detailed business updates, product pipeline information, market size estimates, management biographies, and forward-looking statements, which are characteristic of an Investor Presentation (IP). It is not a formal regulatory report like a 10-K or IR, nor is it merely an announcement of a report's publication (RPA), as it contains substantial content intended for investors. Given the content structure—an invitation to a meeting combined with the actual presentation material detailing strategy, pipeline, and management—the most appropriate classification is Investor Presentation (IP).
2025-05-27 Hebrew (modern)
Company Presentation- 2025
Regulatory Filings Classification · 99% confidence The document text is highly fragmented and contains significant non-standard characters (likely due to encoding issues or being a partial/scanned document), but key structural elements suggest it is a regulatory filing announcement. It mentions dates (27/05/2025, 4.6.2025), company identifiers (BONUS BIOGROUP LTD, TASE website reference), and references to regulatory bodies/systems (isa.gov.il). Crucially, it contains a section titled '���� ������� ������� ����� ��� ������:' (which translates roughly to 'Announcement of the Publication of the Report') and lists a file name '2025-05-27_����_�������_isa.pdf'. The document length is very short (2774 characters). According to Rule 2 (The 'Menu vs Meal' Rule), a short document announcing the publication of a report, rather than containing the full report content, should be classified as a Report Publication Announcement (RPA).
2025-05-27 Russian
Company Presentation, July 2023
Investor Presentation Classification · 98% confidence The document is titled "Bonus Biogroup Company Presentation, July 2023" and contains extensive slides detailing the company's mission, key assets (BonoFill™ and MesenCure™), clinical status, financial updates, and product comparisons. This format, which is designed to inform investors about the company's strategy, products, and recent progress, strongly aligns with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a short announcement (RPA/RNS).
2023-07-11 English
Company Presentation, July 2023
Investor Presentation Classification · 99% confidence The document text contains Hebrew characters and appears to be a formal announcement or filing from 'BONUS BIOGROUP LTD' dated 11/07/2023. Key phrases like '���� ������: ***���� ����� �������***' (which translates roughly to 'Document Title: ***Company Presentation***') and the explicit mention of an attached file named 'Company_Presentation_English_July_2023_isa.pdf' strongly suggest this is an Investor Presentation. The document structure, including sections for presentation details and contact information, aligns with an IP filing. Given the short length (4084 chars) and the nature of presenting information to investors, Investor Presentation (IP) is the most appropriate classification over a full report (like 10-K or IR).
2023-07-11 Russian
Company Presentation
Investor Presentation Classification · 98% confidence The document is structured as a detailed presentation, featuring slides, figures, company history timelines, product descriptions (BonoFill and MesenCure), market analysis, and extensive clinical trial results (preclinical and ongoing Phase I/II trials). The content focuses heavily on scientific and clinical data presentation intended for investors or stakeholders, rather than a formal regulatory filing like a 10-K or a brief earnings release (ER). The format strongly suggests an Investor Presentation (IP) used to communicate strategy, progress, and future outlook to the investment community. It is not a Call Transcript (CT) or a simple announcement (RPA/RNS).
2022-04-11 English
Company Presentation
AGM Information Classification · 95% confidence The document text contains Hebrew characters and appears to be a formal notice or filing related to a company named 'BONUS BIOGROUP LTD'. Key phrases like '���� ������: ***���� ���� �������***' (which translates roughly to 'Subject: ***Notice of General Meeting***' or similar formal announcement) and references to shareholder voting ('���� ���� �������' - shareholder meeting) strongly suggest a corporate governance event. The presence of dates (11/04/2022, 2022-01-038652) and structured sections for voting/resolutions point towards materials prepared for a shareholder meeting. Since it details the meeting structure and likely includes resolutions to be voted upon, it aligns best with materials presented or announced for an Annual General Meeting (AGM). It is not a full 10-K, an earnings release, or a simple director's dealing report. Therefore, AGM-R is the most appropriate classification.
2022-04-11 Russian

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.